Core Viewpoint - The company, Fuhua Jia (敷尔佳), has completed clinical trials for its recombinant type III humanized collagen freeze-dried fiber project and is preparing a summary report for registration application this year [1] Group 1 - The clinical trials for the recombinant type III humanized collagen freeze-dried fiber project have been completed [1] - The company is currently in the stage of preparing the clinical trial summary report [1] - The registration application for the project is expected to be submitted this year [1]

Group 1 - The core viewpoint of the article is that the company, Fuhua Jia (301371), has stated that its directors and senior management currently have no intention to reduce their holdings [1]

Core Viewpoint - The company, Fuhua (301371), is making progress in optimizing its offline channels, which aligns with its expectations, particularly in sales channel and retail terminal optimization [1] Group 1: Channel Optimization - The company is enhancing cooperation with service-oriented distributors through a dual approach of "strong regulation + strong optimization" to strengthen control over the offline market [1] - The focus of the strong regulation is on the meticulous management of inventory levels at agents and retail terminals to avoid stockpiling risks, while ensuring a stable pricing order through comprehensive and continuous dynamic monitoring of the pricing system across all channels [1] - The optimization aspect emphasizes the careful selection of strategic partners among agents and retail terminals, transitioning the channel model from traditional distribution to value-driven sales [1] Group 2: Future Strategies - The company aims to provide more professional and comprehensive product and service support to its partners and end consumers as part of its channel transformation strategy [1]

Group 1: Company Overview - Fulejia is a professional skin care product company focused on R&D, production, and sales of medical devices and functional skin care products, with a multi-channel sales strategy that includes both online and offline platforms [2][3]. - The company has established a comprehensive market reach through major e-commerce platforms like Tmall, Douyin, JD.com, and Pinduoduo, as well as offline channels including specialty cosmetics stores, large supermarkets, chain pharmacies, beauty institutions, and medical facilities [2]. Group 2: Product Registration and R&D - Fulejia has obtained 4 Class II medical device registrations, including products such as medical sodium hyaluronate repair patches and medical recombinant type III humanized collagen patches [3]. - The company has two R&D centers located in Shanghai and Harbin, focusing on raw material development and medical device product R&D, respectively [3]. - In 2025, Fulejia registered 48 cosmetic products, covering various forms such as water, lotion, cream, and essence [4]. Group 3: Clinical Trials and Product Development - The clinical trial for the recombinant type III humanized collagen freeze-dried fiber project has been completed, and the company is preparing the clinical trial summary report for registration submission [4]. - In 2025, the company completed the registration of two new raw materials, which will be developed into products to enhance the product matrix [3]. Group 4: Channel Optimization and Management - The company is optimizing its offline channels, focusing on sales channel and retail terminal improvements, with financial feedback showing some lag [4][5]. - Future strategies include strengthening partnerships with service-oriented distributors and implementing a dual approach of "strong supervision + strong optimization" to enhance market control and stabilize pricing [5]. Group 5: Management and Shareholding - Currently, there is no intention for the company's directors and senior management to reduce their holdings [5].

证券日报网讯2月2日，敷尔佳（301371）在互动平台回答投资者提问时表示，截至2026年1月30日，公 司股东户数为15642户。 ...

Core Viewpoint - On February 2, a total of 7 listed companies had their restricted shares unlocked, with a total market value of approximately 43.65 billion yuan [1] Group 1: Company Specifics - Yunding Technology (Stock Code: 000409) had 4.0062 million shares released from equity incentive restrictions [1] - Jinling Pharmaceutical (Stock Code: 000919) had 220,800 shares released from equity incentive restrictions [1] - Dongfang Chuangye (Stock Code: 600278) had 531,600 shares released from equity incentive restrictions [1] - Xinda Securities (Stock Code: 601059) had 2.551 billion shares released from pre-issue share restrictions [1] - Nuo Si Ge (Stock Code: 301333) had 3.9288 million shares with extended lock-up periods released [1] - Jianghan New Materials (Stock Code: 603281) had 12.2 million shares released from pre-issue share restrictions [1] - Fu Er Jia (Stock Code: 301371) had 250,000 shares with extended lock-up periods released [1]

Market Overview - The cosmetics sector experienced a decline of 0.98% on January 30, with Lafang Family leading the drop [1] - The Shanghai Composite Index closed at 4117.95, down 0.96%, while the Shenzhen Component Index closed at 14205.89, down 0.66% [1] Individual Stock Performance - Qingdao Kingking (002094) saw a closing price of 8.75, with an increase of 4.17% and a trading volume of 1.1682 million shares, amounting to a transaction value of 1.02 billion [1] - Lafang Family (603630) closed at 19.21, down 6.38%, with a trading volume of 89,300 shares and a transaction value of 174 million [2] - Shanghai Jahwa (600315) closed at 20.92, down 4.52%, with a trading volume of 163,300 shares and a transaction value of 345 million [2] - Other notable stocks include Beitaini (300957) at 41.89, down 0.85%, and Marubi (603983) at 31.52, down 0.32% [2] Capital Flow Analysis - The cosmetics sector saw a net inflow of 60.2766 million from institutional investors, while retail investors experienced a net outflow of 62.139 million [2] - The main capital inflow was led by Qingdao Kingking with 68.098 million, while retail investors showed significant outflows across various stocks [3] - Shanghai Jahwa had a net inflow of 6.7524 million from institutional investors, but also faced a net outflow of 7.7544 million from retail investors [3]

中信证券股份有限公司 关于哈尔滨敷尔佳科技股份有限公司首次公开发行前 已发行股份部分解除限售并上市流通的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为哈尔滨敷尔 佳科技股份有限公司（以下简称"敷尔佳"、"公司"、"发行人"）首次公开发行股 票并在创业板上市的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关法律、法规和规范性文件要求，对敷尔 佳首次公开发行前已发行股份部分解除限售并上市流通事项进行了审慎核查，核 查情况及核查意见如下： 一、首次公开发行网下配售股份概况 经中国证券监督管理委员会《关于同意哈尔滨敷尔佳科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2023]1157号）同意注册，并经深圳证券 交易所同意，公司首次公开发行人民币普通股（A股）股票40,080,000股,并于2023 年8月1日在深圳证券交易所创业板上市交易。公司首次公开发行前总股本为 360,000,000股，首次公开发行股票完成后总股本为400,080,000股，其中无限售条 件流通股 ...

证券代码：301371 证券简称：敷尔佳 公告编号：2026-001 哈尔滨敷尔佳科技股份有限公司 关于首次公开发行前已发行股份部分解除限售并 上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 哈尔滨敷尔佳科技股份有限公司（以下简称"公司"或"发行人"）本次解 除限售的股份为公司首次公开发行前已发行的部分限售股。本次解除限售的股东 数量为 1 户，股份数量为 325,000 股，占公司总股本的 0.0625%；本次可实际上 市流通的股份数量为 325,000 股，占公司总股本的 0.0625%。本次解除限售股份 的上市流通日期为 2026 年 2 月 2 日（星期一）。 一、首次公开发行前已发行股份概况 经中国证券监督管理委员会《关于同意哈尔滨敷尔佳科技股份有限公司首次 公开发行股票注册的批复》（证监许可[2023]1157 号）同意注册，并经深圳证 券交易所同意，公司首次公开发行人民币普通股（A 股）股票 40,080,000 股,并 于 2023 年 8 月 1 日在深圳证券交易所创业板上市交易。公司首次公开发行前总 股本为 ...

Market Overview - The cosmetics sector experienced a decline of 1.27% on January 27, with Marubi Biotechnology leading the drop [1] - The Shanghai Composite Index closed at 4139.9, up 0.18%, while the Shenzhen Component Index closed at 14329.91, up 0.09% [1] Individual Stock Performance - Key performers in the cosmetics sector included: - Jiahen Home Cosmetics (300955) with a closing price of 41.47, up 6.88% and a trading volume of 73,900 shares, totaling 303 million yuan [1] - Qingdao Kingway (002094) closed at 8.24, up 3.00% with a trading volume of 569,900 shares, totaling 467 million yuan [1] - Conversely, Marubi Biotechnology (603983) closed at 31.84, down 4.47% with a trading volume of 46,400 shares, totaling 149 million yuan [2] Capital Flow Analysis - The cosmetics sector saw a net outflow of 43.98 million yuan from main funds, while retail investors contributed a net inflow of 43.99 million yuan [2] - Notable capital flows included: - Qingdao Kingway (002094) with a net inflow of 22.70 million yuan from main funds [3] - Shanghai Jahwa (600315) with a net inflow of 8.10 million yuan from main funds [3] - Marubi Biotechnology (603983) experienced a slight net outflow of 94,800 yuan from main funds [3]